Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Net Margin (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Net Margin for 7 consecutive years, with 6.97% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 1210.0% to 6.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 7.14% through Dec 2025, up 266.0% year-over-year, with the annual reading at 5.75% for FY2025, 404.0% up from the prior year.
  • Net Margin hit 6.97% in Q4 2025 for Eton Pharmaceuticals, up from 8.58% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 43.0% in Q1 2021 to a low of 786.32% in Q3 2021.
  • Historically, Net Margin has averaged 66.3% across 5 years, with a median of 9.38% in 2024.
  • Biggest YoY gain for Net Margin was 2358427bps in 2021; the steepest drop was -25621628bps in 2021.
  • Year by year, Net Margin stood at 17.05% in 2021, then tumbled by -37bps to 10.73% in 2022, then plummeted by -171bps to 7.57% in 2023, then soared by 32bps to 5.13% in 2024, then skyrocketed by 236bps to 6.97% in 2025.
  • Business Quant data shows Net Margin for ETON at 6.97% in Q4 2025, 8.58% in Q3 2025, and 13.66% in Q2 2025.